MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
NCT07332182
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location. The evaluation will be performed through clinical, subjective and objective assessments.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Osteochondral Lesions of the Knee Joint
- Osteochondritis Dissecans (OCD)
- Early Osteoarthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Fin-Ceramica Faenza Spa
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Steamboat Orthopaedic & Spine Institute · Steamboat Springs, CO
Illinois · 1
- Genesis Orthopedics & Sports Medicine · Oak Brook, IL
Michigan · 1
- University of Michigan Med school · Ann Arbor, MI
Ohio · 2
- University of Cincinnati Medical Center · Cincinnati, OH
- Ohio State University · Columbus, OH
Oregon · 1
- Oregon Health & Science University in Portland · Portland, OR
Tennessee · 1
- Clinical Research Solutions · Jackson, TN
Texas · 1
- North Texas Medical Research Institute · Rockwall, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.